Search Results

You are looking at 1 - 10 of 56 items for :

Clear All

4293 4300 Llovet, J., Ricci, S., Mazzaferro, V. és mtsai: Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a Phase III randomized

Open access

(HCC) cells and surgically resected HCC tissues. Oncol. Rep. 13 , 1043–1048 (2005). Kojiro S. Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma

Restricted access

Abstract

Chronic hepatitis B virus (HBV) carriers may develop hepatocellular carcinoma (HCC) by a wide range of mechanisms including angiogenesis. We show that HBV replication induces the expression of angiogenic proteins interleukin 6 (IL6) and cyclooxygenase-2 (Cox2). Interestingly, ibuprofen (a Cox2 inhibitor) is found to attenuate the levels of IL6 and Cox 2 which are induced by HBV replication.

The mechanism of attenuation of angiogenic proteins by ibuprofen was further investigated. Our results show that HBx is involved in the increase of the expression of Cox2 through the NFκB pathway. However, the expression of Cox2 is decreased when the HBx-expressing cells are incubated with ibuprofen. The contrasting effect of HBx on Cox2 is found to be determined by differential dimer formation among the members of the NFκB family of proteins, including NFκB, RelA, and C-rel. Specifically, HBx alone results in dimer formation between NFκB and RelA, while the combined presence of HBx and ibuprofen leads to the formation of NFκB and C-rel. Additional information on the interaction network involving HBx, ibuprofen, and NFκB pathways is revealed by two-dimensional liquid chromatography-tandem mass spectrometry proteomics analysis. Taken together, our findings provide new insights on the angiogenesis induced by HBV replication.

Restricted access

228 232 Tarao, K., Takemiya, S., Tamai, S. és mtsai: Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase

Open access

Beasley, R. P., Hwang, L. Y., Lin, C. C. és mtsai: HCC and HBV. A prospective study of 22 707 men in Taiwan. Lancet, 1981, 2 , 1129–1133. Lin C. C. HCC and HBV. A prospective

Restricted access
Orvosi Hetilap
Authors: Evelin Berta, Anna Egresi, Anna Bacsárdi, Zsófia Gáspár, Gabriella Lengyel and Krisztina Hagymási

-acting antivirals. J Hepatol. 2016; 65: 727–733. 23 Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon

Open access

Introduction Hepatocellular carcinoma (HCC) is found within the first five most common tumors worldwide and the prevelance is increasing ( Keating & Santoro, 2009 ; Raza & Sood, 2014 ). HCC treatment includes curative

Restricted access

patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer, 2007, 109 , 1384–1390. Ducreux M. Gemcitabine plus oxaliplatin (GEMOX) in patients with

Open access

Radhika, N. S., Duseja, A., Rajwanshi, A. et al.: Clinico-cytopathological spectrum of HCC, its correlation with serum alpha-fetoprotein level, and hepatitis B and C viral markers. Trop. Gastroenterol., 2004, 25 , 116

Restricted access

Koike, K.: Pathogenesis of HCV-associated HCC: Dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol. Res., 2007, 37 , S115–S120. Koike K

Open access